Comparative Pharmacology
Head-to-head clinical analysis: PORTIA 28 versus TRI LINYAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PORTIA 28 versus TRI LINYAH.
PORTIA-28 vs TRI-LINYAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin release, inhibiting ovulation; progestin (levonorgestrel) alters cervical mucus and endometrial lining.
Combination hormonal contraceptive: ethinyl estradiol and norgestimate. Suppresses gonadotropin release, inhibiting ovulation; also increases cervical mucus viscosity and alters endometrial morphology.
One tablet (levonorgestrel 0.15 mg, ethinyl estradiol 0.03 mg) orally once daily
One tablet orally once daily for 21 days, followed by 7 placebo tablets. Each tablet contains 0.035 mg ethinyl estradiol and 0.180/0.215/0.250 mg norgestimate.
None Documented
None Documented
Levonorgestrel: 24-30 hours; ethinyl estradiol: 12-15 hours. Clinical context: Steady-state achieved within 5-7 days.
Ethinyl estradiol: terminal half-life approximately 17 hours (range 13–27 hours), supporting once-daily dosing; norgestimate's active metabolite norelgestromin: terminal half-life approximately 28 hours.
Renal (60-70% as metabolites, 20-30% as levonorgestrel/ethinyl estradiol glucuronides), fecal (10-20%), biliary (minor).
Ethinyl estradiol is excreted in urine (40%) and feces (60%) as glucuronide and sulfate conjugates; norgestimate is primarily eliminated via renal excretion (46%) and fecal excretion (47%) as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive